Clinical Trials
Source: CCM
- Score: 18Infectious Disease
Immune signatures of vaccine responses in vulnerable populations: Comparison of influenza vaccines
- Ages21 years and older
- GenderBoth
- Score: 17
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention ofInv asive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years VAC52416BAC3001
- Ages60 years and older
- GenderBoth
- Score: 16Melanoma
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
- Score: 15Liver Cancer, Lung Cancer, Melanoma, Gynecological Cancers
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
- Score: 14Phase 1 Cancers
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Score: 13Phase 1 Cancers
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors
- Score: 11Immune System
Characterization of Immune Response to Intradermal Flu Vaccination
- Ages18 years - 40 years
- GenderBoth
- Score: 8Phase 1 Cancers
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
- Score: 7Phase 1 Cancers
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
- Score: 6Infectious Disease, COVID-19 Vaccine
The TIPI Study
- Ages18 years - 65 years
- GenderBoth